02628 Overview

Market Performance: After the Lunar New Year holiday, Chinese H-listed insurers have underperformed, with concerns about short-term profit risks and a lack of disclosed premium income data.

JPMorgan's Analysis: JPMorgan's report indicates that major insurers like PING AN and CHINA LIFE are rated as Overweight, with target prices set at $100 and $40, respectively, due to their recovery in life insurance sales.

Profit Forecasts: JPMorgan forecasts significant growth in FY2025 net profits for CHINA LIFE (47%), PING AN (19%), and CPIC (10%) year-over-year.

Short Selling Activity: There is notable short selling activity in both PING AN and CHINA LIFE, with respective ratios of 28.711% and 16.336%, reflecting market skepticism despite their growth prospects.

Profit Alert Regulations: A-share listed companies in China must issue a profit alert if their annual profit growth exceeds 50%, but CHINA LIFE did not issue one despite a 60.5% YoY profit increase, suggesting a potential net loss in Q4 2025.

Market Performance Concerns: HSBC Global Research indicates that CHINA LIFE may underperform the market due to earnings volatility, while investors are more focused on new business value growth.

Comparison with PING AN: Investors favor PING AN's operating profit after tax, which is less affected by market fluctuations, leading to a more positive outlook for PING AN compared to CHINA LIFE.

Target Prices and Ratings: HSBC has set a target price of $84 and a Buy rating for PING AN's H-shares, while CHINA LIFE's H-shares are rated Hold with a target price of $29.

JPMorgan's Upgrade on Chinese Stocks: JPMorgan upgraded its rating of Chinese stocks to Overweight, citing the end of a four-year downward cycle and a favorable entry point for investors, with year-end targets for the MSCI China Index and CSI 300 Index set at 100 and 5,200, respectively.

Shift in Investment Strategy: The firm anticipates a shift in investor focus from short-term trading to long-term appreciation in Chinese stocks, particularly in sectors benefiting from AI, commodities, and consumer staples.

Highlighted Stocks: JPMorgan's investment strategy includes several Chinese stocks rated as Overweight, such as Tencent, Alibaba, and Moutai, with varying short-selling ratios indicating market sentiment.

Market Outlook: The report reflects a more optimistic outlook for leading internet platforms and sectors like robotics and biotechnology, suggesting potential for outperformance in the Chinese market.

Stock Performance: Several insurance stocks in Hong Kong showed positive movements, with CHINA LIFE increasing by 1.935% and PICC GROUP by 2.744%.

Investment Ratings: Most stocks received a "Buy" rating, including CHINA LIFE, CPIC, and PICC GROUP, while CHINA TAIPING and NCI were rated as "Neutral".

Short Selling Data: Short selling activity varied, with PING AN having the highest short selling amount at $177.33M and a ratio of 22.445%.

Target Price Adjustments: Analysts have adjusted target prices for several stocks, with CHINA LIFE's target raised to HKD40 and PICC P&C's lowered to HKD20.5.

Earnings Announcement Period: The earnings announcement period for Hong Kong/China insurers for FY2025 will start on March 19, led by AIA, PRU, and ZA ONLINE.

Growth Expectations: Citi Research anticipates strong growth in new business value for Chinese life insurers, with China Life, Ping An, and CPIC expected to lead with growth rates of 38%, 32%, and 28%, respectively.

Earnings Forecast: The broker predicts solid earnings growth for FY2025, with significant increases expected for China Taiping, China Life, and NCI, among others.

Short Selling Data: The report includes short selling data for various insurers, indicating varying levels of short selling activity and ratios across different companies.

Stock Performance: CHINA LIFE (02628.HK) saw a stock increase of 1.935%, with short selling amounting to $76.95M and a ratio of 25.746%.

Positive Outlook: Citi Research has opened a positive catalyst watch for CHINA LIFE, anticipating strong FY2025 results and significant new business value growth in 1Q26.

Management Insights: The broker expects management to share favorable updates on 1Q26 new business value growth trends and long-term dividend policies during the FY025 results briefing.

Investment Rating: Citi rated CHINA LIFE as a "Buy" with a target price of $40, citing the company's strong brand, extensive distribution network, and revitalization reform initiatives.